Stricter BP control may have a mortality benefit for persons with high-risk APOL1 genotypes,17 but little is known about whether testing patients for APOL1 risk will affect clinical care processes, including appropriate kidney disease screening, or improve outcomes, such as BP control or incident CKD, or how patients will respond to testing. This evidence concerns the gene APOL1 and kidney disorder.